5ZAN

Crystal Structure of Aurora-A in complex with a new Quinazoline inhibitor

PDB DOI: https://doi.org/10.2210/pdb5ZAN/pdb

Classification: TRANSFERASE/INHIBITOR
Organism(s): Homo sapiens
Expression System: Escherichia coli
Mutation(s): No

Deposited: 2018-02-07 Released: 2019-02-13
Deposition Author(s): Cheng, B., Lu, G., Zhou, H.
Funding Organization(s): National Natural Science Foundation of China

Experimental Data Snapshot

Method: X-RAY DIFFRACTION
Resolution: 2.85 Å
R-Value Free:
0.281 (Depositor), 0.280 (DCC)
R-Value Work:
0.255 (Depositor), 0.250 (DCC)
R-Value Observed:
0.256 (Depositor)

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Ligand Structure Quality Assessment

This is version 1.1 of the entry. See complete history.

Literature

Optimization of Novel Quinazolines as Potent and Orally Bioavailable Aurora Kinase Inhibitors

Long, L., Peng, W., Pan, Y., Cheng, B., Tu, Z., Long, Z., Zhou, H., Liu, Q., Lu, G.

To be published.

Macromolecule Content

Total Structure Weight: 32.99 kDa
Atom Count: 2,008
Modelled Residue Count: 258
Deposited Residue Count: 281
Unique protein chains: 1

Macromolecules

Find similar proteins by:

(by identity cutoff) | 3D Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Aurora kinase A	A	281	Homo sapiens	Mutation(s): 0 Gene Names: AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6 EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for O14965 (Homo sapiens) Explore O14965 Go to UniProtKB: O14965
PHAROS: O14965 GTEx: ENSG00000087586
Entity Groups
Sequence Clusters	30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt Group	O14965
Sequence Annotations Expand
Reference Sequence LOADING

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram	3D Interactions
9A6 (Subject of Investigation/LOI) Query on 9A6 Download Ideal Coordinates CCD File SDF format, chain B [auth A] MOL2 format, chain B [auth A] mmCIF format, chain B [auth A]	B [auth A]	7-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]quinazolin-4-amine C₂₅ H₂₇ N₇ DKCSQCAVMRLWQW-DHZHZOJOSA-N		Interactions Focus chain B [auth A] Interactions & Density Focus chain B [auth A]

Experimental Data & Validation

Experimental Data

Method: X-RAY DIFFRACTION
Resolution: 2.85 Å
R-Value Free: 0.281 (Depositor), 0.280 (DCC)
R-Value Work: 0.255 (Depositor), 0.250 (DCC)
R-Value Observed: 0.256 (Depositor)

Space Group: P 6₁ 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 84.74	α = 90
b = 84.74	β = 90
c = 171.484	γ = 120

Software Package:

Software Name	Purpose
REFMAC	refinement
HKL-2000	data reduction
HKL-2000	data scaling
MOLREP	phasing

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment

Entry History & Funding Information

Deposition Data

Released Date: 2019-02-13

Deposition Author(s):

Funding Organization	Location	Grant Number
National Natural Science Foundation of China	China	81773636

Revision History (Full details and data files)

Version 1.0: 2019-02-13
Type: Initial release
Version 1.1: 2023-11-22
Changes: Data collection, Database references, Refinement description

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.